Compare Bath & Body Works Inc (BBWI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Zoetis Inc — how do they compare? Bath & Body Works Inc trades at $18.46 (market cap $3.81B), while Zoetis Inc trades at $72.76 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 8.2× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays the higher dividend (4.24%). Which is the better fit depends on your goals.
| BBWI | ZTS | |
|---|---|---|
Market Cap | $3.81B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $156.76 |
52-Week Low | $14.85 | $71.91 |
Enterprise Value | $7.70B | $38.70B |
Dividend Yield | 4.24% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $19.32, down 5.11% over 24 hours, with a bearish technical signal and key support at $19. The stock shows attractive valuation metrics, including a P/E of 5.36 and P/S of 0.54, with a net income margin of 10.03% for 2025. Recent developments include expansion into Brazil and a partnership with Ulta Beauty, while Q2 2026 earnings are anticipated on August 26, 2026.
The outlook presents a value opportunity given low valuations and strategic growth initiatives, but risks include declining revenue trends, high debt levels, and negative shareholder equity. Analyst consensus is mixed with a $22.11 price target, suggesting potential upside if turnaround efforts succeed amidst competitive and execution challenges.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
